What the FDA labels say about taking them together
Colchicine and itraconazole
Colchicine's FDA label (Lodoco) of August 13, 2026 names itraconazole in its drug interactions section, and itraconazole's label names colchicine too. The colchicine label: “Significant increases in colchicine plasma levels.”
Check it at the source: the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited); the itraconazole FDA label on DailyMed (effective July 13, 2026, Janssen Pharmaceuticals, Inc.).
What does the colchicine label say about itraconazole?
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), drug interactionsDrug class: Strong CYP3A4 Inhibitors † atazanavir clarithromycin darunavir/ritonavir indinavir itraconazole ketoconazole lopinavir/ritonavir nefazodone nelfinavir ritonavir saquinavir telithromycin tipranavir/ritonavir; Outcome/effect: Significant increases in colchicine plasma levels [see Clinical Pharmacology (12.3)].; Clinical comment: Concomitant use of LODOCO with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4)].
Source: FDA drug label (Lodoco, NDA215727), AGEPHA Pharma USA, LLC, effective August 13, 2026 (SPL set ff06d68f-d65f-d097-e053-6294a90a7e5f), via openFDA
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
What does the itraconazole label say about colchicine?
Itraconazole label, boxed warningCoadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment.
Itraconazole label, contraindicationsIn addition, coadministration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS:
Itraconazole label, drug interactionsMiscellaneous Drugs and Other Substances Colchicine Patients with renal or hepatic impairment:
Tolsura label (Mayne Pharma Commercial LLC, April 23, 2025), boxed warningDrug Interactions Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with TOLSURA because plasma concentrations of such drugs are increased. ( 4.1 , 5.5 , 7.1 ) Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment. ( 4.1 , 7.1 ) Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. …
Source: FDA drug label (Tolsura, NDA208901), Mayne Pharma Commercial LLC, effective April 23, 2025 (SPL set 306352d1-9d5a-49ad-b72d-893b99546861), via openFDA
Source: FDA drug label (SPORANOX), Janssen Pharmaceuticals, Inc., effective July 13, 2026 (SPL set a4d555fa-787c-40fb-bb7d-b0d4f7318fd0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colchicine | Itraconazole | |
|---|---|---|
| Labeled for | Gout | Fungal infections |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.122 per tablet 0.6 mg tablet | $0.910 per capsule 100 mg capsule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once